The Trendlines Group announced it has completed the acquisition of intellectual property developed within the framework of an R&D agreement with Ireland based Endo International plc (Nasdaq:ENDP) (TSX: ENL). The agreement, which was signed in 2012, called for the co-development of novel medical devices and technologies in the areas of men’s health, women’s health and homecare.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.
Trendlines Labs, the technology development incubator of The Trendlines Group, developed cutting-edge medical technologies to meet unmet market needs identified by Endo. Under the acquisition agreement, Trendlines takes commercial responsibility for all intellectual property created in accordance with the parties’ agreement, while Endo benefits from revenues resulting from commercialization. The intellectual property concepts span a number of fields: pain management, urology, oncology, and pelvic health.
Yosi Hazan, CEO of Trendlines Labs, said, “Working closely with Endo, we developed technologies for prostate cancer diagnosis and trans-urethral prostatectomy that are now ready for commercialization. These technological solutions will make a real difference to those who suffer from prostate cancer and BPH.”
D. Todd Dollinger, Chairman and CEO of Trendlines, stated, “Our work with Endo furthers our market reach and is fundamental to our mission — creating and developing companies to improve the human condition.”